Thrombocythemia, Essential: all 195 studies

Page 2 of 2. Open to participants first (45), then studies with results posted, then the rest; newest registration first within each.

• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Lenalidomide and Prednisone in Treating Patients With MyelofibrosisCompletedNCT00227591Phase 2Results posted
• A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia PatientsCompletedNCT00202644Phase 4Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
• Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative NeoplasmsActive, not recruitingNCT06798805
• A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia PatientsActive, not recruitingNCT06514807Phase 3
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Active, not recruitingNCT06456346Phase 3
• Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative NeoplasmsCompletedNCT06371573
• A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingNCT06079879Phase 3
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT05936359Phase 1
• A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ETActive, not recruitingNCT05482971Phase 2
• A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVActive, not recruitingNCT05481151Phase 3
• A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With MyelofibrosisCompletedNCT05044026
• Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative NeoplasmActive, not recruitingNCT05025488Phase 1
• A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid LeukemiaWithdrawnNCT04896112Phase 1
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownNCT04485260Phase 1/2
• Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceActive, not recruitingNCT04285086Phase 3
• Study of Select Combinations in Adults With MyelofibrosisWithdrawnNCT04283526Phase 1
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsActive, not recruitingNCT04279847Phase 1
• IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)Active, not recruitingNCT04262141Phase 2
• Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsCompletedNCT04243122Phase 2
• Jaktinib for the Treatment of Ruxolitinib Intolerance of MyelofibrosisCompletedNCT04217993Phase 2
• PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisWithdrawnNCT04054245Phase 2
• Dual Vaccine Trial in Myeloproliferative NeoplasmsCompletedNCT04051307Phase 1/2
• CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT03972943Early Phase 1
• Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking RuxolitinibTerminatedNCT03935555Phase 1
• The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility PhaseCompletedNCT03907436Not applicable
• MPN-RC 118 AVID200 in MyelofibrosisCompletedNCT03895112Phase 1
• Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.CompletedNCT03869476Not applicable
• Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
• Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)CompletedNCT03745378
• CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative NeoplasmsCompletedNCT03566446Phase 1
• Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of MyelofibrosisTerminatedNCT03373877Phase 1
• Anagre Cap. in Patients With High-Risk Essential ThrombocythemiaCompletedNCT03232177Phase 4
• Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET)CompletedNCT03212053Not applicable
• 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative NeoplasmsTerminatedNCT03121599Not applicable
• 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential ThrombocythemiaStatus unknownNCT03116542Not applicable
• The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineTerminatedNCT02962388Phase 2/3
• Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)CompletedNCT02953704
• Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot StructureCompletedNCT02912884
• Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET PatientsCompletedNCT02893410
• Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative NeoplasmsCompletedNCT02823184
• Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative DisordersWithdrawnNCT02663648
• Hydroxyurea Versus Aspirin and Hydroxyurea in Essential ThrombocythemiaStatus unknownNCT02611973Phase 3
• The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential ThrombocythemiaActive, not recruitingNCT02577926Phase 2
• Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential ThrombocythemiaCompletedNCT02407080Phase 1
• Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutationCompletedNCT02311569Phase 2
• Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
• Anagrelide Retard in Essential ThrombocythemiaCompletedNCT02076815Phase 3
• Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT01998828Phase 2
• Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) PatientsCompletedNCT01970930
• Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative NeoplasmsCompletedNCT01816256Not applicable
• Myeloproliferative Neoplasms and Bone StructureStatus unknownNCT01816022
• Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 2
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
• Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsCompletedNCT01520220Phase 1
• Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisCompletedNCT01433445Phase 1
• Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedNCT01423058Phase 1/2
• Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedNCT01420783Phase 2
• A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid NeoplasmsCompletedNCT01387763Phase 3
• LBH589 (Panobinostat) for the Treatment of MyelofibrosisStatus unknownNCT01298934Phase 1/2
• Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)CompletedNCT01259817Phase 2
• Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia VeraCompletedNCT01243073Phase 2
• Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT01236638Phase 2
• Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential ThrombocythaemiaCompletedNCT01230775Phase 3
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
• Pediatric Disease Registry in Essential Thrombocythaemia (ET)CompletedNCT01198717
• A Study in Myeloproliferative DisordersCompletedNCT01134120Phase 1
• Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential ThrombocythaemiaCompletedNCT01065038Phase 3
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
• Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With MyelofibrosisTerminatedNCT01014546Phase 1
• Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT00935987Phase 1/2
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
• Studying Fentanyl in Patients With CancerTerminatedNCT00899951
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential ThrombocythaemiaStatus unknownNCT00866762Phase 2
• A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic MyelofibrosisCompletedNCT00745550Phase 1/2
• Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET GenesCompletedNCT00715247
• CEP-701 (Lestaurtinib) in MyelofibrosisStatus unknownNCT00668421Phase 1/2
• Research Tissue BankCompletedNCT00666549
• Familial Myeloproliferative DisordersCompletedNCT00666289
• Correlative Biomarker Study in Patients With Myeloproliferative DisordersCompletedNCT00665067
• Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
• Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential ThrombocytosisCompletedNCT00586651Phase 2
• A Safety Study of XL019 in Adults With MyelofibrosisTerminatedNCT00522574Phase 1
• Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
• Molecular Changes and Biomarkers in Chronic Myeloproliferative DisordersCompletedNCT00433862
• Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
• Primary Thrombocythaemia 1 TrialCompletedNCT00175838Not applicable
• Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationCompletedNCT00052520Phase 1/2
• Tipifarnib in Treating Patients With Myelofibrosis and Myeloid MetaplasiaCompletedNCT00047190Phase 2
• Imatinib Mesylate in Treating Patients With MyelofibrosisCompletedNCT00039416Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1

← Thrombocythemia, Essential overview